Iron Chelation Enhances TAM and Triple-Negative Breast Cancer Cell Death
Abstract
T The goal of this study is preclinical testing of Deferiprone (DFP), an iron chelator pre-clinical breast cancer models. DFP increased M1 polarization(even in absence of IL4 or LPS) and in the presence of LPS. DFP enhanced the efficiency of phagocytosis by RAW264.7 cells and was significant in all the culture conditions (p = 0.0004 for Control, p = 0.0007 for IL-4, p = 0.0045 for LPS) but most prominent in the LPS treated group. We measured the tumor cell doubling times including an additional cell line (BT474)and the effect of DFP and found the results similar in all 3 breast cancer cell lines. The IC50 values for the BT474 were similar to the 4T1 and MBA-231 cells. We previously reported the effect of DFP on oxygen metabolism and consumption and extended these results by increasing the n value from n=3 7n=5. Unfortunately, we found no benefit in invivo studies to DFP in enhancing survival in 3 breast cancer models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1208675
Entities
People
- Jason A Koutcher
- Taha Merghoub
Organizations
- Memorial Sloan Kettering Cancer Center